Is a Creatinine Rise of 0.5 mg/dL Every Month Normal in CKD?

1. An underlying cause that is not being adequately treated (e.g., active glomerulonephritis, renovascular disease, uncontrolled diabetes, uncontrolled hypertension)
2. A new superimposed insult — nephrotoxic drugs (NSAIDs, contrast, aminoglycosides), volume depletion, urinary obstruction, or infection
3. Inadequate or suboptimal current therapy

What to Do Next — Step-by-Step

1. Urgent Nephrology Referral

• GFR < 30 mL/min/1.73 m² (Stage G4–G5)
• Albumin-to-creatinine ratio > 300 mg/g (Stage A3)
• Unexplained rapid progression
• Complications difficult to manage

"Although many common problems can be managed with existing guidelines by non-nephrologists, specialty nephrology referral is recommended for patients with an uncertain diagnosis, an albumin to creatinine ratio greater than 300 mg/g, a GFR less than 30 mL/min/1.73 m², or complications that are difficult to manage." — Goldman-Cecil Medicine

2. Identify and Treat the Root Cause

• Is the underlying cause being directly targeted? (diabetic nephropathy → glycemic control; hypertensive nephrosclerosis → BP control; glomerulonephritis → immunosuppression)
• Review for nephrotoxic drugs: avoid NSAIDs, contrast agents, certain antibiotics, herbal remedies
• Rule out obstruction (renal ultrasound), dehydration, or acute-on-chronic kidney injury

3. Optimize Blood Pressure

• Target systolic BP < 130 mmHg (some guidelines recommend < 120 mmHg with standardized measurement)
• First-line: ACE inhibitor or ARB (not both together) — these reduce albuminuria and slow GFR decline
• Additional agents: diuretics, calcium channel blockers
• Finerenone (nonsteroidal mineralocorticoid receptor antagonist) is effective in diabetic CKD with albuminuria: 20 mg/day if GFR > 60, 10 mg/day if GFR 25–59

4. Add SGLT2 Inhibitor (if not already on one)

• Canagliflozin 100 mg/day, Dapagliflozin 5 mg/day, or Empagliflozin 10 mg/day
• Reduces albuminuria, slows GFR decline, and reduces risk of kidney failure and cardiovascular events
• Works in both diabetic and non-diabetic CKD with albuminuria
• Not approved in type 1 diabetes

"Sodium glucose cotransporter-2 inhibitors can slow the rate of progression of chronic kidney disease and have become a cornerstone of therapy." — Goldman-Cecil Medicine

5. Diet Optimization

• Dietary protein: 0.6–0.8 g/kg/day at Stage G3–G5 (reduces solute load and may slow progression)
• Total energy intake: 25–35 kcal/kg/day to avoid malnutrition on low-protein diet
• Sodium: < 2 g/day especially with hypertension
• Involve a registered dietitian nutritionist — essential
• Mediterranean or DASH-sodium diet patterns are beneficial

6. Treat Metabolic Acidosis

• If serum bicarbonate < 22 mEq/L:
• Start sodium bicarbonate 650 mg twice daily, titrate to target bicarb of 22–24 mEq/L
• This slows GFR decline independent of whether frank acidosis is present

7. GLP-1 Agonists (if diabetic)

• Agents like semaglutide/liraglutide also reduce albuminuria and slow GFR decline in type 2 diabetes with albuminuria — consider if not already on one

8. Lipid Management and Cardiovascular Risk

• Statins are recommended to lower LDL and reduce the very high cardiovascular risk in CKD
• Note: lipid-lowering agents do NOT directly slow kidney disease progression, but CKD patients die more often from CVD than from kidney failure

9. Plan for Renal Replacement Therapy (if approaching ESRD)

• If GFR is declining this fast, start early education about hemodialysis, peritoneal dialysis, and transplant options
• Early intervention significantly extends time before kidney failure (as shown by GFR decline curves comparing early vs. late intervention)

Summary Table

How to Rule Out Glomerulonephritis (GN) in a CKD Patient

Step 1 — Clinical Clues (History & Examination)

• Tea-colored or cola-colored urine (gross hematuria)
• Facial/periorbital edema, especially in the morning
• Hypertension that is new or worsening
• Recent infection — sore throat or skin infection 1–3 weeks ago (post-streptococcal GN)
• Systemic symptoms — joint pain, rash (lupus), hemoptysis (pulmonary-renal syndrome, anti-GBM/Goodpasture), sinusitis (ANCA vasculitis), purpuric rash (IgA vasculitis)
• Rapid deterioration of kidney function (oliguria, fluid retention)

"Glomerulonephritis classically presents with hematuria (gross or microscopic), proteinuria, hypertension, and acute kidney injury... A number of systemic diseases may have their initial presentation with glomerulonephritis, so a careful examination for signs and symptoms of multisystem disease should be sought." — Campbell Walsh Wein Urology

Step 2 — Urinalysis with Microscopy (Most Important Initial Test)

Step 3 — Quantify Proteinuria

• Spot urine albumin-to-creatinine ratio (ACR) or protein-to-creatinine ratio (PCR)
• 24-hour urine protein if precise quantification is needed
• > 3.5 g/day = nephrotic range → membranous nephropathy, FSGS, minimal change, amyloid
• Sub-nephrotic proteinuria with hematuria = nephritic picture → IgA nephropathy, post-infectious GN, lupus nephritis, MPGN, ANCA vasculitis

Step 4 — Serological Blood Tests (Targeted by Clinical Pattern)

Complement levels

"Hypocomplementemia, defined by a low C3 level when combined with normal C4 levels, is strongly supportive of a diagnosis of acute postinfectious glomerulonephritis or C3 glomerulopathy, and a low C3 and low C4 focuses the diagnosis on either lupus nephritis or membranoproliferative glomerulonephritis." — Campbell Walsh Wein Urology

Additional serology based on suspicion:

Step 5 — Imaging

• Renal ultrasound: Check for kidney size, echogenicity, symmetry, cortical thinning, and obstruction
  • Bilateral small echogenic kidneys → chronic GN with irreversible fibrosis (biopsy may not be helpful)
  • Normal-sized or enlarged kidneys → active disease, biopsy still informative
  • Rules out obstruction as a cause of creatinine rise
• Chest X-ray / CT chest: If pulmonary-renal syndrome suspected (anti-GBM, ANCA) — look for alveolar hemorrhage

Step 6 — Kidney Biopsy (Definitive Test)

• Proteinuria > 1 g/day with or without hematuria and the cause is unclear
• Serological tests are inconclusive
• Nephrotic syndrome of unclear etiology
• Rapidly progressive GN (RPGN) — urgent biopsy
• Suspected secondary GN (lupus, vasculitis) requiring histological confirmation before immunosuppression

• Light microscopy (cell proliferation, crescent formation, sclerosis)
• Immunofluorescence (IgA, IgG, IgM, C3, C1q deposits — pattern localizes the type)
• Electron microscopy (subepithelial, subendothelial, or mesangial deposits)

• Classic post-streptococcal GN in a child with elevated ASO, low C3, typical course → clinical diagnosis sufficient; C3 returning to normal within 8–12 weeks confirms it

Summary — "Rule Out" Algorithm

Urine dipstick + microscopy
        ↓
No hematuria, no casts, minimal protein → GN UNLIKELY
        ↓
Hematuria (dysmorphic RBCs/RBC casts) + proteinuria → GN LIKELY
        ↓
Check C3, C4
        ↓
Add targeted serology (ANCA, ANA, anti-GBM, ASO, HBsAg, HCV, HIV)
        ↓
Renal ultrasound (size, echogenicity, obstruction)
        ↓
If cause still unclear or treatment decision requires it → KIDNEY BIOPSY

What is a Kidney Biopsy For — and What Can It Tell You?

The Core Purpose

"Ideally, analysis of a kidney biopsy sample should identify a specific diagnosis, reflect the level of disease activity, and provide information to allow informed decisions about treatment." — Comprehensive Clinical Nephrology, 7th Edition

1. What exactly is the diagnosis?
2. How active/reversible is the disease right now?
3. How much permanent damage has already been done?

When Is It Done? (Indications)

How Is It Done?

What the Biopsy Tells You — The Three Microscopy Layers

1. Light Microscopy (LM)

• Cell proliferation — abnormal increase in cells = active inflammation
• Crescents — a hallmark of rapidly progressive GN (RPGN); a crescent is a mass of cells filling Bowman's capsule, indicating severe injury. More crescents = worse prognosis
• Nodular sclerosis (Kimmelstiel-Wilson nodules) = diabetic nephropathy
• Focal segmental glomerulosclerosis (FSGS) — scarring of parts of some glomeruli
• Mesangial expansion — earliest change in diabetic nephropathy
• Tubular atrophy and interstitial fibrosis — the amount of fibrosis tells you how much is irreversible (chronic damage that cannot be reversed by any treatment)
• Membranous changes — thickening of the capillary wall

2. Immunofluorescence (IF)

• IgA deposits in the mesangium → IgA nephropathy (most common GN worldwide)
• IgG + C3 granular subepithelial deposits → Membranous nephropathy
• Linear IgG along the GBM → Anti-GBM disease (Goodpasture)
• "Full house" pattern (IgG + IgA + IgM + C3 + C1q all present) → Lupus nephritis — this pattern is virtually diagnostic of SLE
• C3-dominant deposits, no Ig → C3 glomerulopathy
• ANCA vasculitis / pauci-immune GN → No or minimal deposits (pauci-immune = little to no immune deposits)

"Particular biopsy findings highly characteristic of lupus nephritis include glomerular deposits that stain dominantly for IgG with co-deposits of IgA, IgM, C3, and C1q — the so-called 'full house' immunofluorescence pattern." — National Kidney Foundation Primer on Kidney Diseases, 8e

3. Electron Microscopy (EM)

• Subepithelial deposits (on the outer side of GBM, between GBM and podocyte foot processes) → Membranous nephropathy
• Subendothelial deposits (inner side of GBM, facing the blood) → Lupus class III/IV, MPGN
• Mesangial deposits → IgA nephropathy, early lupus
• GBM thinning → Thin basement membrane disease (benign familial hematuria)
• GBM splitting/lamellation ("basket weave") → Alport syndrome (genetic)
• Podocyte foot process effacement (fusion) → Minimal change disease, FSGS
• Tubuloreticular inclusions in endothelial cells → Lupus nephritis ("interferon footprints")
• Dense intramembranous deposits → Dense deposit disease (C3 glomerulopathy)

What the Biopsy Report Actually Tells the Clinician

When Biopsy Is NOT Needed (or Too Risky)

• Small, shrunken kidneys on ultrasound — mostly fibrosis; biopsy is risky and unlikely to change management
• Classic post-streptococcal GN in a child with typical course and rising C3 — clinical diagnosis is sufficient
• Typical diabetic nephropathy with long-standing diabetes, retinopathy, and gradual proteinuria — biopsy only if something atypical appears
• Absolute contraindications: uncontrolled hypertension, bleeding disorder, single kidney (relative), uncooperative patient

Bottom Line for Your CKD Patient

• Is GN the cause — and which type?
• How much kidney is still salvageable (active inflammation vs. irreversible fibrosis)
• Should immunosuppression be started — and which agent?
• What is the realistic prognosis for this individual kidney?

Ultrasound First — Then Nephrology Referral for Biopsy Decision

Why Ultrasound Must Come Before Biopsy

• Yields mostly scar tissue (non-diagnostic)
• Carries high bleeding risk (less parenchyma, more fragile tissue)
• Will not change management

The textbooks are explicit: "If kidney ultrasound reveals small kidneys or a significant size difference, it is prudent not to perform a kidney biopsy." — Comprehensive Clinical Nephrology, 7th Edition

• Confirm which kidney to biopsy
• Identify the lower pole (safest entry point)
• Avoid cysts, large vessels, or anomalies

What Ultrasound Findings Tell You Before Biopsy

The Correct Sequence for Your Patient

Rising creatinine despite treatment
          ↓
1. Urine dipstick + microscopy (RBC casts? Proteinuria?)
2. Blood: C3, C4, ANA, ANCA, anti-GBM, ASO, HBsAg, HCV, HIV
3. Renal ultrasound
          ↓
Ultrasound shows normal-sized kidneys + no obstruction
          ↓
4. Refer to nephrology with all results
          ↓
Nephrologist decides on biopsy (timing, safety, likely yield)

Why the Nephrologist Makes the Biopsy Decision

• Is the clinical + serological picture already diagnostic enough? (e.g., classic post-streptococcal GN may not need biopsy)
• Is there enough active disease left to treat?
• What is the bleeding risk for this specific patient (BP controlled? Platelets? INR?)
• Will the biopsy class (e.g., lupus class III vs. V) meaningfully change the drug choice?

Practical Recommendation

• Renal ultrasound
• Full urine microscopy + ACR
• Serological panel (C3, C4, ANA, ANCA, anti-GBM, HBsAg, HCV, HIV)